Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532542 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
A Phase 3 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT03532542 is a Phase 3 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 171 participants.
The verdict
NCT03532542, a Phase 3 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Interventions
- DRUG Casimersen
- DRUG Golodirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532542
The ClinicalTrials.gov registry entry for NCT03532542 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Casimersen is the first listed.
NCT03532542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03532542 about?
NCT03532542 is a clinical study titled "An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy". The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
What is the current status of trial NCT03532542?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2018-08-02. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT03532542?
The interventions under investigation include: Casimersen (DRUG), Golodirsen (DRUG).
Who is sponsoring clinical trial NCT03532542?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.